Literature DB >> 29264439

Direct acting antiviral agents and hepatocellular carcinoma development: don't take it for granted.

Antonio Riccardo Buonomo1, Ivan Gentile1, Guglielmo Borgia1.   

Abstract

Entities:  

Year:  2017        PMID： 29264439      PMCID： PMC5723742          DOI： 10.21037/tgh.2017.11.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  14 in total

1.  Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.

Authors:  Lauren A Beste; Pamela K Green; Kristin Berry; Matthew J Kogut; Stephen K Allison; George N Ioannou
Journal:  J Hepatol       Date:  2017-03-04       Impact factor: 25.083

2.  Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.

Authors:  Calogero Cammà; Giuseppe Cabibbo; Antonio Craxì
Journal:  J Hepatol       Date:  2016-05-30       Impact factor: 25.083

3.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

4.  Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Authors:  Salvatore Petta; Marco Marzioni; Pierluigi Russo; Alessio Aghemo; Alfredo Alberti; Antonio Ascione; Andrea Antinori; Raffaele Bruno; Savino Bruno; Antonio Chirianni; Giovanni Battista Gaeta; Edoardo G Giannini; Manuela Merli; Vincenzo Messina; Simona Montilla; Carlo Federico Perno; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Francesca Ceccherini Silberstein; Erica Villa; Anna Linda Zignego; Luca Pani; Antonio Craxì
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-04-10

5.  Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.

Authors:  M R Pinzone; A M Zanghì; L Rapisarda; V D'Agata; F Benanti; D Spartà; G Nunnari; B Cacopardo
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014-12       Impact factor: 3.507

6.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer Kramer; Steven M Asch; Maneerat Chayanupatkul; Yumei Cao; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

7.  The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.

Authors:  Ivan Gentile; Alberto Enrico Maraolo; Antonio Riccardo Buonomo; Emanuela Zappulo; Guglielmo Borgia
Journal:  Expert Opin Drug Discov       Date:  2015-11-12       Impact factor: 6.098

8.  HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.

Authors:  George N Ioannou; Pamela K Green; Kristin Berry
Journal:  J Hepatol       Date:  2017-09-05       Impact factor: 25.083

9.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal; Graham R Foster; William L Irving
Journal:  J Hepatol       Date:  2016-07-05       Impact factor: 30.083

10.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal
Journal:  J Hepatol       Date:  2016-01-30       Impact factor: 30.083
View more
  3 in total

1.  Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).

Authors:  Ivan Gentile; Riccardo Scotto; Carmine Coppola; Laura Staiano; Daniela Caterina Amoruso; Teresa De Simone; Federica Portunato; Stefania De Pascalis; Salvatore Martini; Margherita Macera; Giulio Viceconte; Grazia Tosone; Antonio Riccardo Buonomo; Guglielmo Borgia; Nicola Coppola
Journal:  Hepatol Int       Date:  2018-12-06       Impact factor: 6.047

2.  Hepatocellular carcinoma after direct-acting antivirals: an unresolved problem. Review of five cases.

Authors:  Agnieszka Joanna Bartosiewicz; Tomasz Mikuła
Journal:  Clin Exp Hepatol       Date:  2019-02-20

3.  Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort).

Authors:  Antonio Riccardo Buonomo; Riccardo Scotto; Carmine Coppola; Biagio Pinchera; Giulio Viceconte; Costanza Maria Rapillo; Laura Staiano; Mariarosaria Saturnino; Ferdinando Scarano; Federica Portunato; Mariantonietta Pisaturo; Stefania De Pascalis; Salvatore Martini; Grazia Tosone; Salvatore Nappa; Nicola Coppola; Ivan Gentile
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.